Screener
aTyr Pharma ATYR CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating lease liability | (399) | (341) |
| Net cash used in operating activities | (21,868) | (29,314) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (211) | (9) |
| Purchases of available-for-sale investment securities | (13,846) | (41,260) |
| Maturities of available-for-sale investment securities | 40,873 | 40,150 |
| Net cash provided by (used in) investing activities | 26,816 | (1,119) |
| Cash flows from financing activities: |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's capex?
- aTyr Pharma (ATYR) reported capex of $73K in Q2 2026.
- How has aTyr Pharma's capex changed year-over-year?
- aTyr Pharma's capex increased by 711.1% year-over-year, from $9K to $73K.
- What is the long-term trend for aTyr Pharma's capex?
- Over 4 years (2021 to 2025), aTyr Pharma's capex has grown at a -20.4% compound annual growth rate (CAGR), from $192K to $77K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about aTyr Pharma's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude